The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an incision to get a bone marrow sample — or make a larger incision and remove a section of bone via surgery.
But the days of using bone biopsies to guide treatment for multiple myeloma and other cancers, such as many types of leukemia, may be numbered.
A new University of Kansas research effort featured in the current edition of Integrative Biology has resulted in a low-cost, reliable blood test that uses a small plastic chip about the size of a credit card that can deliver the same diagnostic information as a bone biopsy — but using a simple blood draw instead.
“For the last 10 years, we’ve been developing a blood-based test for a variety of cancer diseases — one of them is multiple myeloma,” said Steven Soper, Foundation Distinguished Professor of Chemistry and Mechanical Engineering at KU and a member of The University of Kansas Cancer Center, who led the research. “We’ll be able to eliminate the need for bone-marrow biopsies and allow the clinician to determine the best way to treat the disease using a blood draw. From this test, the clinician will be able to determine the stage of the disease, what type of drug will best treat the disease and monitor for signs of recurrence if the disease goes into remission.”
Soper, who also serves as director of the Center of BioModular Multi-scale System for Precision Medicine at KU and KU Medical Center, said that previous plastic chips to test for multiple myeloma had shortcomings, such as picking up regular blood cells instead of multiple myeloma cells in the blood. By contrast, the new chip developed at KU vastly improves testing performance and accuracy over previous chips for multiple myeloma.
High levels of circulating multiple myeloma cells are linked with more aggressive disease and worse outcomes, so a sensitive test is vital for assessing the state of the disease in a patient and devising the most effective therapy.
“We get very few blood cells,” Soper said. “Only multiple myeloma cells. So, the ability for us to efficiently detect those cells is very high and thus, diagnose the disease at a more treatable stage.”
Moreover, other attempts to create chips that test for multiple myeloma have proven to be complicated and expensive to manufacture.
“The chip we’re using, because it is made from a plastic, can be injection molded, the same method that is used to produce CDs, DVDs and Blu-ray Discs,” Soper said. “What’s really nice is we can produce these chips for a couple of dollars per chip, which makes it really appropriate for testing in a clinical setting.”
Soper’s co-authors on the paper are Joyce Kamande, Maria Lindell and Peter Voorhees of the University of North Carolina at Chapel Hill and Ma?gorzata Witek of KU.
The new test for multiple myeloma developed by the team will be brought to market by BioFluidica, a San Diego-based company with a research lab in Lawrence and a clinical testing lab planned for the KU Medical Center very soon.
“BioFluidica has been around for about two years now and is making excellent progress in bringing this chip-based technology to market,” Soper said. “Patients will soon be benefiting from this technology. We’re already doing clinical testing on different diseases using this technology at Children’s Mercy Hospital in Kansas City on pediatric patients with acute leukemia. It’s the same premise — we are looking for tumor cells in blood to see signs of disease recurrence, negating the need for a bone biopsy.”
Indeed, the KU researcher said the new technology developed by his team could have applications across many cancers, making diagnostics easier for patients and clinicians, and helping usher in more tailored therapies that could improve patient outcomes.
“We’ve demonstrated the utility of this technology in a variety of cancer diseases,” Soper said. “Here, we’re homing in on multiple myeloma, but we’ve developed tests for two forms of leukemia and for pancreatic cancer, prostate cancer, ovarian cancer, colorectal cancer and breast cancer. With our technology, we’ll be able to see if patients are developing cancers before they have overt symptoms and help improve survival.”
Soper noted the technology could be ideal for patients living far from major medical facilities, such as those living in rural regions.
“Some of this technology can be really important to areas that don’t have high-end cancer screening tools and thus must travel to a major cancer center to be treated,” he said. “For instance, this test can be conducted in a doctor’s office in a place like Hays, Kansas.”
For Soper, the work on the microfluidic technology goes beyond academic or entrepreneurial interests — like so many Americans, his life has been touched by cancer.
“This is very important to me,” he said. “Just like a lot of people, I’ve experienced a family member dying of cancer. My dad passed away from colon cancer, and he never had a colonoscopy. A lot of the technology we’re developing can minimize the need for these invasive screening technologies like colonoscopies and bone biopsies. This is important for screening but also to assist doctors to provide the correct medication to patients and monitor for recurrence.”
The researcher envisions a day where screening for a broad array of cancers would be routine and widespread, long before symptoms present themselves in patients.
“At some point, you’ll just go in for your yearly physical where they’ll do a blood draw anyway,” he said. “But then they’ll screen it for cancer.”
The Latest on: Cancer detection
via Google News
The Latest on: Cancer detection
- Tennis Star Chris Evert Reveals Stage 1C Ovarian Cancer Diagnosis—Here's What That Meanson January 18, 2022 at 12:38 pm
Tennis legend Chris Evert, who won the world No. 1 spot in tennis seven times, has been diagnosed with ovarian cancer. Evert, 67, revealed her diagnosis in a story written for ESPN, co-authored by her ...
- Biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapyon January 18, 2022 at 12:20 pm
A new data portal called Cancer-Immu established by a team of biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. With data ...
- Lynsey Bennett shares cervical cancer signs before diagnosis and update on 'crucial' treatmenton January 18, 2022 at 12:15 pm
Lynsey Bennett has been reflecting on her health journey five years after she was first diagnosed with cervical cancer. The Longford native has shared the first signs that something wasn't right at ...
- CalPERS board president announces resignation after cancer diagnosison January 18, 2022 at 9:35 am
CalPERS Board of Administration President Henry Jones is resigning from the board Friday to focus on his recovery from cancer, he told the board over the weekend. Jones told the California Public ...
- What Happens When Lung Cancer Screening Targets Nonsmokers?on January 18, 2022 at 9:31 am
Lung cancer screening promotion in a population with a low smoking prevalence was associated with a significant amount of overdiagnosis, an analysis involving women in Taiwan found. In the ...
- Criss Angel Announces His 7-Year-Old Son Johnny Is in Remission After Cancer Diagnosison January 18, 2022 at 9:28 am
Criss Angel and his wife, Shaunyl Benson, are also the parents of son Xristos, 2, and daughter Illusia, 2 months — details ...
- Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adultson January 18, 2022 at 5:05 am
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, ...
- Chris Evert's ovarian cancer diagnosis: What to know about preventionon January 17, 2022 at 11:22 am
Tennis legend Chris Evert recently revealed that she is battling stage 1C ovarian cancer. The 67-year-old tennis legend who has won 18 Grand Slam singles titles and three Grand Slam doubles titles ...
- What a terminal cancer diagnosis is teaching this neuroscientist about the human mindon January 17, 2022 at 9:20 am
Neuroscientist David J. Linden unpacks what he's learned about how the human mind works in the face of impending death.
via Bing News